Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
By R. Stupp, S. Taillibert, A. Kanner, S. Kesari, D. Steinberg, S. Toms, L. Taylor, F. Lieberman, A. Silvani, K. Fink and 20 more. Journal of the American Medical Association (JAMA), 2015
1,187 citations recorded by the source corpus.
Subfields: Biotechnology, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/03df874780fb9bdc1d029ea684ee2bab3285e6af
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017, neutral): “5 13 (9-18) 5 (2-11) 8 (2-14) Abbreviation: TTFields, tumor-treating fields.”
- Glioblastoma: Overview of Disease and Treatment (2016, background): “Optune plus TMZ demonstrated superior PFS of 7.1 months versus 4 months with TMZ alone, as well as superior OS of 20.5 months versus 15.6 months with TMZ alone (Stupp et al., 2015).”